Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.

Waldencast plc

Waldencast is a self-described global beauty and wellness multi-brand platform.

Waldencast

Waldencast is a holding company and investment fund that incubates and accelerates early stage beauty and wellness brands and helps them rapidly create scale and profitability via industry specific operational expertise. Waldencast invests in brand-led business models and goes beyond traditional incubation and acceleration to develop a collective of innovative and unique brands that place responsible entrepreneurship at the heart of its operations.  Waldencast has offices in New York and London and has an investment portfolio in North America, Europe, and Latin America.

The selection of brands to participate in the community is as much driven by the strength of the brand concept and business model as it is by our shared human and social values: sustainability, responsibility, inclusivity.  We believe brands that marry purpose, art, beauty, and design with industry and commerce to make the planet and the lives of those in it better.

Individuals that are part of the Waldencast collective are as much driven by the strength of the brands’ ideas, as it is by sharing our dreamer/maker values: ambition with humility, idealism with practicality, grit with empathy, vision with action.

We have the spirit of a challenger, a disruptor, a game-changer. We are a start-up and we intend to stay in the attitude of a start-up regardless of our success.

Costa Brazil

2024 AWARD WINNING BROW SERUM🎉

InStyle has recognized Obagi Nu-Cil™ Eyebrow Boosting Serum as the Best Brow Serum in their Best Beauty Buys 2024 product roundup! 

“I was introduced to this powerhouse brow serum by board-certified dermatologist Mona Gohara, M.D.  …So it's safe to say I'm hooked.” writes Kara Jillian Brown

Thank you to our Obagi Fam and healthcare providers for the continuous love you show our products.

Visit your Obagi provider to learn more about this great product! 
#obagi #obagimedical #obagiskincare

Read the full article here:
https://lnkd.in/giiJuG-M

We're #hiring a new Amazon Brand Manager in Greater London, England. Apply today or share this post with your network.

Congratulations to our portfolio company C16 Biosciences for this recognition!

We are excited to participate in TD Cowen’s 8th annual conference 2024 with Oliver Chen, CFA and Jonna Kim, CFA.

We’re #hiring a new Glaze North America Key Account Director in United States. Apply today or share this post with your network.

	Dec '20	Dec '21	Dec '22	Dec '23
revenue	94.43M -	142.47M 50.88%	166.13M 16.61%	218.14M 31.30%
cost of revenue	29.10M -	55.04M 89.16%	126.70M 130.20%	137.06M 8.18%
gross profit	65.33M -	87.44M 33.83%	39.44M 54.90%	81.08M 105.60%
selling and marketing expenses		73.83M -
general and administrative expenses		9.13M -
selling general and administrative expenses	60.42M -	82.97M 37.32%	109.30M 31.74%	159.81M 46.21%
research and development expenses	4.38M -	6.09M 38.99%	4.40M 27.74%	3.19M 27.42%
other expenses	-11K -	817K 7,527.27%
cost and expenses	93.90M -	144.10M 53.46%	240.40M 66.83%	300.07M 24.82%
operating expenses	64.80M -	89.06M 37.43%	113.70M 27.67%	163.01M 43.36%
interest expense	6.28M -	11.12M 77.01%	12.88M 15.87%	18.91M 46.76%
ebitda	13.94M -	13.10M 6.04%	-39.10M 398.54%	-21.43M 45.18%
operating income	528K -	-1.63M 407.77%	-74.27M 4,470.40%	-81.93M 10.32%
depreciation and amortization	13.42M -	13.90M 3.60%	35.17M 152.96%	60.50M 72.01%
total other income expenses net	-11K -	2.77M 25,272.73%	-73.03M 2,737.59%	-31.01M 57.54%
income before tax	-5.76M -	-9.97M 73.04%	-147.30M 1,376.88%	-112.94M 23.33%
income tax expense	-3.39M -	9.60M 382.91%	-5.69M 159.26%	-6.97M 22.58%
net income	-2.37M -	-19.58M 725.99%	-116.62M 495.75%	-89.98M 22.85%
weighted average shs out	11.68M -	8.00M 31.50%	107.56M 1,244.56%	91.16M 15.25%
weighted average shs out dil	11.68M -	8.00M 31.50%	107.56M 1,244.56%	91.16M 15.25%
eps	-0.20 -	-2.45 1,125%	-1.08 55.92%	-0.99 8.33%
epsdiluted	-0.20 -	-2.45 1,125%	-1.08 55.92%	-0.99 8.33%

NASDAQ:WALD

Waldencast

Last Close

3.47

26/07 20:00

Market Cap

456.93M

Beta: -

Volume Today

73.17K

Avg: 5.58K

PE Ratio

−2.75

PFCF: 366.52

Preview